Drug Type Autologous CAR-T |
Synonyms TAA5-CAR-T, TAA-05 |
Target |
Action inhibitors |
Mechanism FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors), Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseClinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Myeloid Leukemia | Phase 2 | China | 20 Aug 2021 | |
Refractory acute myeloid leukemia | Clinical | China | 01 Jul 2021 |